Silicon Laboratories Inc. | ||||
Condensed Consolidated Statements of Cash Flows | ||||
(In thousands) | ||||
(Unaudited) | ||||
| ||||
|
Three Months Ended |
| ||
|
March 31,
|
|
April 1,
|
|
Operating Activities |
|
|
|
|
Net income |
$ 26,405 |
|
$ 15,426 |
|
Adjustments to reconcile net income to cash provided by operating activities: |
|
|
|
|
Depreciation of property and equipment |
3,704 |
|
3,596 |
|
Amortization of other intangible assets and other assets |
6,427 |
|
6,752 |
|
Amortization of debt discount and debt issuance costs |
3,169 |
|
869 |
|
Stock-based compensation expense |
12,192 |
|
10,486 |
|
Deferred income taxes |
(4,780) |
|
(4,059) |
|
Changes in operating assets and liabilities: |
|
|
|
|
Accounts receivable |
(3,307) |
|
(1,252) |
|
Inventories |
(3,368) |
|
(1,636) |
|
Prepaid expenses and other assets |
(17,169) |
|
6,708 |
|
Accounts payable |
13,030 |
|
5,565 |
|
Other current liabilities and income taxes |
(9,643) |
|
(2,944) |
|
Deferred income, deferred revenue and returns liability |
(2,599) |
|
4,038 |
|
Other non-current liabilities |
(1,849) |
|
(1,536) |
|
Net cash provided by operating activities |
22,212 |
|
42,013 |
|
|
|
|
|
|
Investing Activities |
|
|
|
|
Purchases of available-for-sale investments |
(52,821) |
|
(267,777) |
|
Sales and maturities of available-for-sale investments |
128,975 |
|
25,595 |
|
Purchases of property and equipment |
(4,102) |
|
(4,543) |
|
Purchases of other assets |
(4,698) |
|
(1,446) |
|
Acquisition of business, net of cash acquired |
-- |
|
(13,658) |
|
Net cash provided by (used in) investing activities |
67,354 |
|
(261,829) |
|
|
|
|
|
|
Financing Activities |
|
|
|
|
Proceeds from issuance of long-term debt, net |
-- |
|
390,000 |
|
Payments on debt |
-- |
|
(72,500) |
|
Payment of taxes withheld for vested stock awards |
(17,871) |
|
(13,553) |
|
Proceeds from the issuance of common stock |
1,211 |
|
162 |
|
Net cash provided by (used in) financing activities |
(16,660) |
|
304,109 |
|
|
|
|
|
|
Increase in cash and cash equivalents |
72,906 |
|
84,293 |
|
Cash and cash equivalents at beginning of period |
269,366 |
|
141,106 |
|
Cash and cash equivalents at end of period |
$342,272 |
|
$225,399 |
|